^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WM-A1-3389

    i
    Other names: WM-A1-3389, WM-A1, AR044, AR0 44, WM A1, WM A1 3389, AR-044, WMA1, WMA13389
    Associations

    News

    Trials
    Company:
    WMBIO, Y-Biologics
    Drug class:
    IGSF1 inhibitor
    Associations

    News

    Trials
    almost2years
    Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) (clinicaltrials.gov)
    P1, N=54, Recruiting, Wellmarker Bio | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 underexpression • PD-L1-L
    |
    Keytruda (pembrolizumab) • WM-A1-3389
    over2years
    Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (KEYNOTE-E90) (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, Wellmarker Bio | Trial completion date: Sep 2025 --> Feb 2026 | Initiation date: Aug 2023 --> Jan 2024 | Trial primary completion date: Sep 2025 --> Feb 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 underexpression • PD-L1-L
    |
    Keytruda (pembrolizumab) • WM-A1-3389
    almost3years
    Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, Wellmarker Bio
    New P1 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 underexpression • PD-L1-L
    |
    Keytruda (pembrolizumab) • WM-A1-3389